USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Mar 23, 2022 | Dec 2021 | $-0.57 | - | $-0.91 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Mar 23, 2022 | Dec 2021 | $2.90M | - | $2.58M |
Htg Molecular Diagnostics, Inc's next earnings date is Wednesday, Mar 23, 2022 for the fiscal quarter ending Dec 2021.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 4 | $-2.00 | $-2.54 | $-1.68 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2022 | 0 / 0 | $-2.00 | $-2.31 | $-2.33 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 4 | $17.21M | $13.50M | $22.00M |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Nov 8, 2021 | Sep 2021 | $-0.70 | - | - |
| Aug 12, 2021 | Jun 2021 | $-0.77 | $-0.65 | 15.23% |
| May 13, 2021 | Mar 2021 | $-0.98 | $-0.80 | 18.64% |
| Mar 25, 2021 | Dec 2020 | $-1.12 | $-0.91 | 18.51% |
| Nov 10, 2020 | Sep 2020 | $-1.05 | $-1.05 | - |
| Aug 11, 2020 | Jun 2020 | $-1.25 | $-1.18 | 5.32% |
| May 13, 2020 | Mar 2020 | $-1.05 | $-1.20 | -14.29% |
| Mar 25, 2020 | Dec 2019 | $-1.45 | $-0.15 | 89.66% |
| Nov 12, 2019 | Sep 2019 | $-2.48 | $-2.25 | 9.09% |
| Aug 6, 2019 | Jun 2019 | $-2.29 | $-2.55 | -11.48% |
| May 9, 2019 | Mar 2019 | $-2.93 | $-2.85 | 2.56% |
| Mar 7, 2019 | Dec 2018 | $-2.66 | $-1.05 | 60.56% |
| Nov 8, 2018 | Sep 2018 | $-2.85 | $-2.55 | 10.53% |
| Aug 7, 2018 | Jun 2018 | $-3.00 | $-2.10 | 30.00% |
| May 10, 2018 | Mar 2018 | $-3.83 | $-3.20 | 16.27% |
| Mar 22, 2018 | Dec 2017 | $-4.58 | $-2.25 | 50.82% |
| Nov 7, 2017 | Sep 2017 | $-7.80 | $-6.90 | 11.54% |
| Aug 8, 2017 | Jun 2017 | $-8.63 | $-9.00 | -4.35% |
| May 15, 2017 | Mar 2017 | $-10.50 | $-10.95 | -4.29% |
| Mar 23, 2017 | Dec 2016 | $-11.40 | $-11.40 | - |
| Nov 14, 2016 | Sep 2016 | $-12.68 | $-13.80 | -8.88% |
| Aug 9, 2016 | Jun 2016 | $-14.25 | $-14.70 | -3.16% |
| May 12, 2016 | Mar 2016 | $-12.30 | $-15.30 | -24.39% |
| Mar 25, 2016 | Dec 2015 | $-11.93 | $-7.05 | 40.88% |
| Nov 12, 2015 | Sep 2015 | $-0.85 | $-0.76 | 10.59% |
| Aug 6, 2015 | Jun 2015 | $-0.70 | $-1.73 | -147.14% |
| May 6, 2015 | Mar 2015 | - | $-0.73 | - |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Mar 25, 2021 | Dec 2020 | $-4.80 | $-4.34 | - |
| Mar 25, 2020 | Dec 2019 | $-0.55 | $-7.80 | - |
| Mar 7, 2019 | Dec 2018 | $-0.70 | $-8.90 | - |
| Mar 22, 2018 | Dec 2017 | $-2.03 | $-29.10 | - |
| Mar 23, 2017 | Dec 2016 | - | $-55.20 | - |
| Mar 25, 2016 | Dec 2015 | - | $-10.27 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Nov 8, 2021 | Sep 2021 | $2.58M | - | - |
| Aug 12, 2021 | Jun 2021 | $2.07M | $2.07M | 1.00% |
| May 13, 2021 | Mar 2021 | $1.69M | $1.44M | 0.85% |
| Mar 25, 2021 | Dec 2020 | $2.32M | $2.58M | 1.11% |
| Nov 10, 2020 | Sep 2020 | $2.23M | $1.78M | 0.80% |
| Aug 11, 2020 | Jun 2020 | $1.79M | $1.96M | 1.10% |
| May 13, 2020 | Mar 2020 | $3.04M | $2.23M | 0.73% |
| Mar 25, 2020 | Dec 2019 | $4.85M | $4.80M | 0.99% |
| Nov 12, 2019 | Sep 2019 | $5.47M | $5.40M | 0.99% |
| Aug 6, 2019 | Jun 2019 | $5.56M | $5.80M | 1.04% |
| May 9, 2019 | Mar 2019 | $2.73M | $3.20M | 1.17% |
| Mar 7, 2019 | Dec 2018 | $8.16M | $7.73M | 0.95% |
| Nov 8, 2018 | Sep 2018 | $5.11M | $4.71M | 0.92% |
| Aug 7, 2018 | Jun 2018 | $5.29M | $4.91M | 0.93% |
| May 10, 2018 | Mar 2018 | $4.97M | $4.16M | 0.84% |
| Mar 22, 2018 | Dec 2017 | $6.98M | $7.90M | 1.13% |
| Nov 7, 2017 | Sep 2017 | - | $3.72M | - |
| Aug 8, 2017 | Jun 2017 | - | $1.76M | - |
| May 15, 2017 | Mar 2017 | - | $1.37M | - |
| Mar 23, 2017 | Dec 2016 | - | $1.46M | - |
| Nov 14, 2016 | Sep 2016 | - | $913.90K | - |
| Aug 9, 2016 | Jun 2016 | - | $1.90M | - |
| May 12, 2016 | Mar 2016 | - | $865.23K | - |
| Mar 25, 2016 | Dec 2015 | - | $1.22M | - |
| Nov 12, 2015 | Sep 2015 | - | $1.01M | - |
| Aug 6, 2015 | Jun 2015 | - | $790.55K | - |
| May 6, 2015 | Mar 2015 | - | $1.02M | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Mar 25, 2021 | Dec 2020 | $8.25M | $8.55M | 3.62% |
| Mar 25, 2020 | Dec 2019 | $19.25M | $19.20M | -0.24% |
| Mar 7, 2019 | Dec 2018 | $21.96M | $21.50M | -2.08% |
| Mar 22, 2018 | Dec 2017 | $13.80M | $14.76M | 6.95% |
| Mar 23, 2017 | Dec 2016 | - | $5.13M | - |
| Mar 25, 2016 | Dec 2015 | - | $4.04M | - |
HTGM's next earnings date is Wednesday, Mar 23, 2022 for the fiscal quarter ending Dec 31, 2021.
According to analysts, the average EPS estimation for Htg Molecular Diagnostics, Inc's next quarterly earnings is $-0.57, with a low EPS estimation of $-0.78, and a high estimation of $-0.41.
Over the last 1 month, EPS estimates have seen 0 upward revisions and 0 downward. The EPS 1 month trend is $-0.57, the last 2 month trend is $-0.61, and the 3 month trend is $-0.61.
Based on analysts, the average revenue estimation is $2.90M, with a low revenue estimation of $2.70M, and a high estimation of $3.01M.
Htg Molecular Diagnostics, Inc's previous earnings date was Nov 8, 2021 for its fiscal quarter ended Sep 30, 2021.
Htg Molecular Diagnostics, Inc's previous annual earnings date was Mar 25, 2021 for its fiscal year ended Dec 31, 2020.
HTGM's earnings per share (EPS) was $-4.34, beating the consensus analysts forecast of $-4.80 by -9.51% , and higher than the previous year's EPS (Dec 2019) by -44.31%.
Revenues were $8.55M, better than the forecast of $8.25M by 3.62%, and down by -55.48% from previous year's revenue.
The company reported a net income of $-20.87M.
Htg Molecular Diagnostics, Inc reported a free cash flow of $-16.75M for its fiscal year, compared to $-17.80M a year ago.
The company ended the fiscal year with $12.28M in total debt, an increase of 15.61% compared to the previous year.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.
